LONDON, Jan. 26 -- The government of the United Kingdom issued the following news:
The Medicines and Healthcare products Regulatory Agency (MHRA) has formally begunits year aschair of the Access Consortium for 2026, marking a new phase of international regulatory collaboration aimed at strengthening patient access to safe, effective medicines.
The Access Consortium -comprisingregulatory authorities from the UK, Australia, Canada,Singaporeand Switzerland - works together to streamline regulatory processes, support innovation and improve global public health outcomes.
Lawrence Tallon, MHRA Chief Executive, said the Agency is committed to advancing the Consortium's reputation as a trusted, forward-looking network.
"On behalf of themedicinesregulatory agencies in the UK, Canada,Australiaand Singapore, I would like to thank our colleaguesatSwissMedicfor expertly chairing Access in 2025. 2026 will be an important year for theConsortiumin which we jointly drive forward the delivery of our excitingGROWTHmanifesto.We willbuild onourstrong foundations and deliver real benefits for patients and industryacross our five partner countries and the global community," he said.
For more informationvisit theAccess Consortium Website.
Disclaimer: Curated by HT Syndication.
